Raphael, A.; Dudnik, E.; Hershkovitz, D.; Jain, S.; Olsen, S.; Soussan-Gutman, L.; Ben-Shitrit, T.; Dvir, A.; Nechushtan, H.; Peled, N.;
et al. FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC). J. Clin. Med. 2022, 11, 2475.
https://doi.org/10.3390/jcm11092475
AMA Style
Raphael A, Dudnik E, Hershkovitz D, Jain S, Olsen S, Soussan-Gutman L, Ben-Shitrit T, Dvir A, Nechushtan H, Peled N,
et al. FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC). Journal of Clinical Medicine. 2022; 11(9):2475.
https://doi.org/10.3390/jcm11092475
Chicago/Turabian Style
Raphael, Ari, Elizabeth Dudnik, Dov Hershkovitz, Suyog Jain, Steve Olsen, Lior Soussan-Gutman, Taly Ben-Shitrit, Addie Dvir, Hovav Nechushtan, Nir Peled,
and et al. 2022. "FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)" Journal of Clinical Medicine 11, no. 9: 2475.
https://doi.org/10.3390/jcm11092475
APA Style
Raphael, A., Dudnik, E., Hershkovitz, D., Jain, S., Olsen, S., Soussan-Gutman, L., Ben-Shitrit, T., Dvir, A., Nechushtan, H., Peled, N., Onn, A., Agbarya, A., & on behalf of the Israel Lung Cancer Group.
(2022). FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC). Journal of Clinical Medicine, 11(9), 2475.
https://doi.org/10.3390/jcm11092475
